Why ReMedium
The product is safe with no chemical modifications in the HA, even after high cross-linking process.
- Shows higher volume effect compared to other fillers of same amount
- Excellent volumizing effect and easy molding even with a small amount
Shaping the Future of Aesthetic Medicine
ReMedium shapes a direction
where innovation is
purposeful, regeneration is
intelligent, and aesthetic
outcomes continue to evolve.
Our purpose is clear: to keep aesthetics in its prime
We believe aesthetics is never static. It continuously evolves through the people, ideas, and technologies shaping the industry—becoming more advanced, precise, and meaningful over time
ReMedium contributes to this evolution by developing solutions that deliver natural-looking results and reliable clinical performance, aligned with the future of aesthetic medicine.
Our purpose is clear: to keep aesthetics in its prime
We believe aesthetics is never static. It continuously evolves through the people, ideas, and technologies shaping the industry—becoming more advanced, precise, and meaningful over time
ReMedium contributes to this evolution by developing solutions that deliver natural-looking results and reliable clinical performance, aligned with the future of aesthetic medicine.
Regeneration is at the core of our vision. Through advanced solutions that support long-term skin vitality, enhance natural beauty, and promote continuous improvement, ReMedium combines Korean innovation with advanced formulation science to create treatments designed for modern aesthetics.
To us, being in your prime is not about perfection. It is about preserving confidence, vitality, and relevance through solutions that feel natural, refined, and authentic. This belief guides our philosophy, innovation, and commitment to excellence.
Prime Beyond Boundaries
Leading With Integrity
QUALITY & PRECISION
ReMedium develops regenerative aesthetic solutions using high-grade raw materials and advanced manufacturing under strict quality standards, ensuring consistent safety, purity, and reliability.
CLINICAL PERFORMANCE
Driven by continuous research and innovation, ReMedium products are supported by clinical experience and internationally recognized certifications, including CE, CPNP, ISO, GMP, KFDA, and MDSAP, delivering safe and predictable aesthetic outcomes.
PROFESSIONAL SUPPORT
Through F18 HUB, ReMedium provides healthcare professionals with expert training, clinical protocols, seminars, and educational resources to promote safe practice and continuous professional development.
CEO Message
Shaping the Future of
Aesthetics Together
Since our beginning, we have been driven by a simple belief: true innovation in aesthetics comes from understanding people, advancing science, and creating solutions that make a meaningful difference.
As a Korean aesthetic company, we are dedicated to developing safe, effective, and high-quality technologies that support practitioners and help people feel confident in their own beauty. For us, this means looking beyond trends and focusing on what truly matters—quality, trust, and solutions that can make a positive difference in everyday clinical practice.
“We believe meaningful progress comes from listening and learning. “
Together, we continuously pursue excellence to deliver trusted aesthetic solutions with integrity and responsibility. As we continue our journey, we remain committed to innovation, collaboration, and building lasting partnerships around the world.
We are grateful to everyone who has supported ReMedium along the way. Every partnership, every conversation, and every shared experience has helped shape who we are today. We look forward to continuing this journey with the same curiosity, responsibility, and commitment that have guided us from the beginning.
Thank you for considering ReMedium as your trusted partner in shaping the future of aesthetics.
Kanan Ahmadov
CEO & Founder
2026
.
Exorem Skin & Hair Duo debuted
Advanced exosome-based systems Exorem Skin & Hair make its market debut
Rosarem PLLA enters the market
Rosarem PLLA marks a new step in biostimulation
2024
.
Pharmaceutical license obtained
Secured a Pharmaceutical License, expanding our capabilities within the pharmaceutical sector
Remitox 100U Botulinum Toxin debuted
Botulinum Toxin Type A, produced using advanced vacuum dehydration technology
2022
.
ReMedium Silk, Yellow Bottle
Launching CPNP Certified regenerative hair and fat-dissolving solutions
ReMedium 50 & ReMedium 100, ReMedium Full launched
Expanding our portfolio with high-performance body fillers
2020
.
ReMedium Aqua launched
Launch of CPNP Marked ReMedium Aqua HA Skin booster
CE CertifIied ReMedium Vline
Launch of ReMedium Vline PDO Threads
CE Mark obtained for ReMedium Vline
2016-2018
.
ReMediumSky CE MDR Certification
Korea’s First CE MDR Certification Secured
ReMediumSky CE MDR Certification
Bio-regenerative recombinant Type I & III collagen booster by ReMedium officially introduced
.
2025
Global Regulatory Achievements
Key regulatory milestones achieved across SFDA, INVIMA, COFEPRIS, EUDAMED reaching 85+ registrations worldwide
ReMedium PDRN reaches 3,000,000 syringes sales
ReMedium PDRN reaches 3,000,000 syringes sales globally, reflecting continued clinical adoption
.
2023
F18 Academy established
F18 Academy established to support professional education and clinical training
ODM Platform initiated
ReMedium PDRN reaches 3,000,000 syringes sales globally, reflecting continued clinical adoption
.
2021
ReMedium PDRN launched
Introduction of ReMedium PDRN, the
highest-concentration PDRN solution in the market
.
2019
CE Mark for ReMedium HA Fillers
CE certification secured, marking the ReMedium’s HA Fillers first step into the European market
ReMedium Brand launched
Launch of ReMedium Fine, Mid, Sub-Q and
ReMedium Advance Soft & Hard HA Fillers
2026
.
Exorem Skin & Hair Duo debuted
Advanced exosome-based systems Exorem Skin & Hair make its market debut
Rosarem PLLA enters the market
Rosarem PLLA marks a new step in biostimulation
2024
.
Pharmaceutical license obtained
Secured a Pharmaceutical License, expanding our capabilities within the pharmaceutical sector
Remitox 100U Botulinum Toxin debuted
Botulinum Toxin Type A, produced using advanced vacuum dehydration technology
2022
.
ReMedium Silk, Yellow Bottle
Launching CPNP Certified regenerative hair and fat-dissolving solutions
ReMedium 50 & ReMedium 100, ReMedium Full launched
Expanding our portfolio with high-performance body fillers
2020
.
ReMedium Aqua launched
Launch of CPNP Marked ReMedium Aqua HA Skin booster
CE CertifIied ReMedium Vline
Launch of ReMedium Vline PDO Threads
CE Mark obtained for ReMedium Vline
2016-2018
.
ReMediumSky CE MDR Certification
Korea’s First CE MDR Certification Secured
ReMediumSky CE MDR Certification
Bio-regenerative recombinant Type I & III collagen booster by ReMedium officially introduced
.
2025
Global Regulatory Achievements
Key regulatory milestones achieved across SFDA, INVIMA, COFEPRIS, EUDAMED reaching 85+ registrations worldwide
ReMedium PDRN reaches 3,000,000 syringes sales
ReMedium PDRN reaches 3,000,000 syringes sales globally, reflecting continued clinical adoption
.
2023
F18 Academy established
F18 Academy established to support professional education and clinical training
ODM Platform initiated
Initiating ODM platform for international
aesthetic partners
.
2021
ReMedium PDRN launched
Introduction of ReMedium PDRN, the
highest-concentration PDRN solution in the market
.
2019
CE Mark for ReMedium HA Fillers
CE certification secured, marking the ReMedium’s HA Fillers first step into the European market
ReMedium Brand launched
Launch of ReMedium Fine, Mid, Sub-Q and
ReMedium Advance Soft & Hard HA Fillers